Atlas Trials

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

Clinical trial NCT01948830 · COMPLETED

Trial details

NCT number
NCT01948830
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Age-related Macular DegenerationChoroidal Neovascularization
Start date
2013-12-17
Primary completion
2015-11-19
Enrollment
650

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.